Mirae Asset Global Investments
CRVS icon

Mirae Asset Global Investments’s Corvus Pharmaceuticals CRVS Stock Holding History

Mirae Asset Global Investments’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.2K Sell
3,761
-546
-13% -$7.58K ﹤0.01% 1340
2026
Q1 		$63K Buy
4,307
+678
+19% +$10.8K ﹤0.01% 1252
2025
Q4 		$27.9K Buy
3,629
+748
+26% +$5.9K ﹤0.01% 1496
2025
Q3 		$21.2K Sell
2,881
-98
-3% -$502 ﹤0.01% 1485
2025
Q2 		$11.9K Buy
2,979
+931
+45% +$3.39K ﹤0.01% 1467
2025
Q1 		$6.92K Sell
2,048
-93
-4% -$438 ﹤0.01% 1498
2024
Q4 		$11.2K Buy
+2,141
New +$16K ﹤0.01% 1501

Other funds holding CRVS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
FMI
F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return
TE
Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mirae Asset Global Investments's CRVS Position: Q2 2026 in Review

Mirae Asset Global Investments reduced its Corvus Pharmaceuticals (CRVS) stake by 13% in Q2 2026, selling an estimated $7.58K and leaving 3,761 shares worth $56.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1340.

Mirae Asset Global Investments first reported a position in CRVS in Q4 2024 and has held it in 7 quarters since. The position peaked at $63K in Q1 2026. 59 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Mirae Asset Global Investments held 3,761 shares of Corvus Pharmaceuticals worth $56.2K as of Q2 2026.
  • Mirae Asset Global Investments sold 546 Corvus Pharmaceuticals shares in Q2 2026, an estimated $7.58K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1340 holding.
  • Mirae Asset Global Investments first reported a position in Corvus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Mirae Asset Global Investments's Corvus Pharmaceuticals position peaked at $63K in Q1 2026.
  • 59 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.